
Targeted radiopharmaceutical therapy has entered mainstream oncology through the clinical success of prostate-specific membrane antigen (PSMA)-directed imaging and [ 177 Lu] Lu-PSMA-617 therapy. However, heterogeneous antigen expression, acquired resistance, lineage plasticity, and nonresponding lesions show that a cancer cell-centric strategy cannot fully address the ecological complexity of advanced malignancy. The tumor microenvironment (TME) offers a complementary target space because stromal, vascular, immune, and chemokine-driven niches are functionally required for tumor growth and are often more genomically stable than malignant cells. This review synthesizes the biological rationale, radiochemical design, clinical translation, and current limitations of TME-targeted radiopharmaceuticals, focusing on fibroblast activation protein (FAP), integrins, and the CXCR4/CXCL12 axis. The authors discuss first-generation FAP inhibitor (FAPI) tracers and therapeutic limitations caused by short tumor residence, and then compare next-generation strategies, including dimerization, multimerization, albumin-binding motifs, peptide-based ligands such as FAP-2286, and newer FAPI-derived therapeutic constructs. They also reassess RGD-based integrin targeting as a clinically informative but heterogeneous angiogenesis platform, and summarize CXCR4-directed pentixather therapy in hematological malignancies and selected solid tumor models. Finally, they examine radionuclide selection, dosimetry, patient selection, and combination strategies with chemotherapy, antiangiogenic therapy, immune checkpoint blockade, cytokine therapy, and cell-based therapy. TME-targeted radiopharmaceuticals are unlikely to replace tumor cell-directed theranostics; rather, their most important role may be to reshape resistant tumor ecosystems and rationally extend precision radionuclide therapy beyond single-antigen paradigms.
Background: Hepatocellular carcinoma (HCC) remains the major cause of cancer-related mortality worldwide due to high postoperative recurrence rates and limited treatment options for minimal residual disease (MRD). Methods: In this study, glypican-3 (GPC3)-targeted radiopharmaceutical, Lu-177-DOTA-GPC3, was developed and evaluated as a potential adjuvant targeted radionuclide therapy for HCC. The anti-GPC3 monoclonal antibody was conjugated with DOTA and radiolabeled with Lu-177 under systematically optimized conditions. Optimization of the chelator-to-antibody ratio, pH, temperature, and incubation time was performed to maximize the radiochemical yield while preserving antibody immunoreactivity and structural integrity. The radioconjugate was purified and characterized using instant thin-layer chromatography and size-exclusion high-performance liquid chromatography. In vitro stability was assessed in phosphate-buffered saline and human serum, while cellular binding and internalization studies were conducted using GPC3-expressing HepG2 cells. In vivo biodistribution, pharmacokinetics, and therapeutic efficacy were evaluated in the tumor-bearing mice. Results: The developed radioconjugate demonstrated high radiolabeling efficiency (96.8% +/- 1.2%) and radiochemical purity (>98%) with excellent stability (>95% up to 72 h). Batch-to-batch reproducibility showed minimal variability across independent preparations. Strong receptor-specific cellular binding (similar to 82%) and significant internalization were observed, confirming preservation of the biological activity following radiolabeling. Biodistribution studies demonstrated high tumor uptake (18.6% +/- 2.1%ID/g at 48 h) with favorable tumor-to-background ratios. Therapeutic evaluation revealed up to 66.4% tumor growth inhibition and significantly prolonged survival without observable systemic toxicity. Conclusions: Findings support the potential of the Lu-177-DOTA-GPC3 as a promising theranostic radionuclide platform for targeting GPC3-positive HCC and addressing postoperative MRD-associated recurrence.
Background: Macrophage migration is vital in cancer therapy, as it contributes to the elimination of cancer cells and enables targeted drug delivery. However, the natural migratory ability of macrophage is limited, and the location of cancer cells are dynamic and uncertain. Methods: To address this issue, we propose a hierarchical framework based on exploration and exploitation to enable autonomous macrophage migration. Specifically, the upper layer employs a particle filter to explore cancer cell location by sensing signaling molecule concentrations. This information is then passed to the middle layer, which applies the maximum Shannon entropy sampling principle to determine the optimal movement position. Finally, the lower layer utilizes optogenetics to guide migration toward targets, which constitutes exploitation. The interaction among the layers enables autonomous macrophage migration. Results: Simulation results verify the effectiveness of the proposed framework, demonstrating that the macrophage successfully eliminates the cancer cell even when the target location is unknown. Furthermore, the results reveal that the proposed framework achieves higher targeting precision compared to both greedy and nonlayered strategies, thereby enhancing the accuracy of cancer cell elimination and targeted drug delivery. Conclusions: This study highlights the potential translational value for improving targeted cancer therapy.
Radioimmunotherapy (RIT) represents a paradigm shift in precision cancer therapy by integrating the molecular specificity of monoclonal antibodies with the cytotoxic potential of therapeutic radionuclides. However, the therapeutic success of RIT is not merely associated with targeted radiation delivery but also depends on complex interplay of radiobiology, tumor immunology, antibody pharmacology, and patient-specific dosimetry. This review explores the molecular and cellular mechanisms, including DNA damage response, immunogenic cell death, tumor microenvironment remodeling, cytokine signaling, and bystander/abscopal effects of RIT. The role of key pharmacological determinants such as target antigen selection, antibody engineering, radionuclide chemistry, radiolabeling strategies, pharmacokinetics, biodistribution, and personalized dosimetry will also be evaluated for therapeutic effectiveness of RIT. Furthermore, translational challenges such as heterogeneous antigen expression, limited tumor penetration, dosimetric uncertainty, and immune-mediated therapeutic resistance in addition to logistical barriers have also been discussed.
Aim: The objective of this study was to assess the anticancer efficacy of ED5, a new oleanolic acid (OA) analogue and selective casein kinase 1 alpha (CK1 alpha) inhibitor, and to ascertain if focused ultrasound (FUS) can improve its delivery and therapeutic effect against glioma. The authors carried out in vitro, in vivo, and mechanistic studies incorporating ultrasound-mediated drug delivery, building on the chemical synthesis of ED5 with OA as the main ingredient.Methods: The intratumoral penetration of ED5 in glioma cells and xenograft-bearing mice was enhanced by focused ultrasonic exposure. Cell counting kit-8 assays were used to measure cell viability to calculate IC20 values and proliferative capability. Clonogenic survival was evaluated using crystal violet staining. Kinase activity was assessed by kinome profiling. Molecular docking, isothermal titration calorimetry, and surface plasmon resonance were used to confirm the binding between ED5 and CK1 alpha. Changes in molecular expression brought on by ED5 with or without FUS were measured using quantitative polymerase chain reaction and immunohistochemistry.Results: When compared with OA, ED5 dramatically reduced the ability of human glioma cell lines U118MG and LN229 to proliferate and form colonies. The antiproliferative effects of ED5 were further amplified by FUS, which increased its absorption in glioma cells. Without causing any discernible systemic toxicity, the combination of ED5 and FUS in vivo resulted in a greater suppression of tumor growth than ED5 alone. According to mechanistic research, ED5 selectively binds CK1 alpha and inhibits its kinase activity. Endoplasmic reticulum stress (ERS), reactive oxygen species (ROS) buildup, and activation of the JNK/c-Jun branch of the Mitogen-activated protein kinase (MAPK) signaling pathway were all brought on by this suppression. By increasing the effectiveness of ED5 administration, FUS further enhanced these molecular effects.Conclusions: ED5 targets CK1 alpha and modulates the MAPK-ROS-ERS signaling pathway to demonstrate strong anticancer efficacy against glioblastoma. A novel ultrasound-enhanced biotherapy approach for glioma care is highlighted by FUS, which dramatically increases ED5 intratumoral delivery and therapeutic efficacy.